Inactive Instrument

News MRI Interventions Inc OTC Bulletin Board

Equities

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

ClearPoint Neuro Says Partner AviadoBio Treats First Person in Trial of AVB-101 for Frontotemporal Dementia	Apr. 16	MT
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations	Apr. 16	GL
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)	Apr. 08	PR
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency	Mar. 20	AQ
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency	Mar. 19	AQ
Stifel Adjusts Price Target on ClearPoint Neuro to $9 From $8, Maintains Buy Rating	Mar. 13	MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Transcript : ClearPoint Neuro, Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
Earnings Flash (CLPT) CLEARPOINT NEURO Posts Q4 Revenue $6.8M, vs. Street Est of $6.5M	Mar. 12	MT
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results	Mar. 12	AQ
ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024	Mar. 12	CI
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System	Mar. 11	AQ
ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery	Mar. 11	CI
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024	Mar. 04	AQ
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024	Mar. 01	AQ
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock	Mar. 01	AQ
ClearPoint Neuro to Seek Acquisitions	Mar. 01	CI
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock	Feb. 29	AQ
ClearPoint Neuro Launches Proposed Public Offering of Common Stock	Feb. 28	AQ
ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model	Feb. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News MRI Interventions Inc OTC Bulletin Board

Equities

Summary

Filters